AminoChain is a technology company.
AminoChain has raised $5.0M across 1 funding round.
AminoChain has raised $5.0M in total across 1 funding round.
AminoChain has raised $5.0M in total across 1 funding round.
AminoChain's investors include Alumni Ventures, Pareto Holdings.
AminoChain is a health-tech startup founded in 2022 that builds a blockchain-based decentralized platform connecting biobanks, clinical sites, and biopharma companies to facilitate biosample exchange and enable decentralized healthcare applications.[1][2][3][4] Its flagship product, the Specimen Center, creates a marketplace where researchers can locate, license, and track biosamples, while patients and donors gain transparency, control, and potential revenue from their samples.[2][3][4] Serving biobanks (tracking ~350 million biospecimens from 100,000+ patients), researchers at pharma companies, NIH, and universities, AminoChain solves the problem of underutilized biosamples—90% of ~200 million U.S. samples sit unused due to discovery and access barriers—by tokenizing them as NFTs for traceability and monetization.[1][3] The company has raised ~$7-7.8 million across pre-seed/seed rounds from investors like Andreessen Horowitz (a16z), Antler, Plug and Play, and Cercano, achieving incubator/accelerator stage with a 14-person team and partnerships with 22 biobanks.[1][2][3]
AminoChain was founded in late 2022 by James Barnes (27-year-old entrepreneur) and Max Matthews (self-taught engineer met at a New York hackathon), alongside a team blending blockchain, bioethics, lifesciences expertise—many with PhDs or pharma backgrounds, including a former chief revenue officer of a major biosample marketplace.[3] The idea emerged from recognizing biobanking inefficiencies: fragmented inventories across ~2,500 U.S. biobanks hinder research, with biosamples hard to find and track.[3] Early traction came via accelerators like Antler and Plug and Play, raising initial $500K, followed by $7M+ from a16z and others to build the "Amino Node" software and Specimen Center.[1][2][3] Pivotal moments include onboarding 22 biobanks, tracking 350M biospecimens, and serving 100 researchers, humanizing the mission through patient empowerment.[3]
AminoChain rides the DeSci (decentralized science) and Web3 healthcare trends, merging blockchain with biotech to decentralize biobanking amid rising demand for personalized medicine and real-world evidence.[1][2][3] Timing aligns with post-pandemic data-sharing needs and regulatory pushes for patient-centric research, amplified by blockchain's maturity in supply chain tracking (e.g., NFTs for provenance).[3] Market forces like biopharma's $100B+ R&D spend on underutilized samples favor it, reducing preclinical timelines via efficient access.[3] It influences the ecosystem by empowering donors, streamlining ~$5B biobanking market, and inspiring Web3 apps in healthcare, potentially setting standards for transparent, incentivized data economies.[2][4]
AminoChain is poised to scale its network, targeting more biobanks and global expansion while launching additional dApps on its protocol amid DeSci growth.[2][3] Trends like AI-driven drug discovery and tokenized real-world assets will amplify its momentum, potentially capturing significant biobanking market share as patient ownership norms evolve.[3] Its influence may grow by bridging traditional biotech with Web3, transforming biosamples from static assets to dynamic, revenue-generating protocol layers—unlocking the full potential of global inventories for faster innovation.[1][2]
AminoChain has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in September 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2024 | $5.0M Seed | Alumni Ventures, Pareto Holdings |